United States Guidelines on Dyslipidemia. Strengths and Weaknesses

Juan Pedro-Botet; Juan J. Chillarón; David Benaiges; Juana A. Flores Le-Roux

doi:10.1016/S1131-3587(15)70120-2

United States Guidelines on Dyslipidemia. Strengths and Weaknesses

Juan Pedro-Botet, Juan J. Chillarón, David Benaiges, Juana A. Flores Le-Roux

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

© 2015 Sociedad Española de Cardiología. The American College of Cardiology and the American Heart Association have produced new guidelines on cholesterol levels and the risk of atherosclerotic cardiovascular disease that represent a paradigm shift in the treatment of hypercholesterolemia because they abandon the use of the low-density lipoprotein cholesterol level as the therapeutic target and focus instead on the clinical benefits of statins. This article presents the key features of these guidelines and highlights both their strengths and areas open to improvement.

Original language	English
Pages (from-to)	18-21
Journal	Revista Espanola de Cardiologia Suplementos
Volume	15
Issue number	S1
DOIs	https://doi.org/10.1016/S1131-3587(15)70120-2
Publication status	Published - 1 Jan 2015

Keywords

Cardiovascular disease
Cardiovascular risk
Cholesterol
Clinical guidelines
Statins

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1131-3587(15)70120-2

Cite this

@article{7964982de7094ff8afd6ac2c4873f0ec,

title = "United States Guidelines on Dyslipidemia. Strengths and Weaknesses",

abstract = "{\textcopyright} 2015 Sociedad Espa{\~n}ola de Cardiolog{\'i}a. The American College of Cardiology and the American Heart Association have produced new guidelines on cholesterol levels and the risk of atherosclerotic cardiovascular disease that represent a paradigm shift in the treatment of hypercholesterolemia because they abandon the use of the low-density lipoprotein cholesterol level as the therapeutic target and focus instead on the clinical benefits of statins. This article presents the key features of these guidelines and highlights both their strengths and areas open to improvement.",

keywords = "Cardiovascular disease, Cardiovascular risk, Cholesterol, Clinical guidelines, Statins",

author = "Juan Pedro-Botet and Chillar{\'o}n, {Juan J.} and David Benaiges and {Flores Le-Roux}, {Juana A.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/S1131-3587(15)70120-2",

language = "English",

volume = "15",

pages = "18--21",

journal = "Revista Espanola de Cardiologia Suplementos",

issn = "1131-3587",

publisher = "Ediciones Doyma, S.L.",

number = "S1",

}

TY - JOUR

T1 - United States Guidelines on Dyslipidemia. Strengths and Weaknesses

AU - Pedro-Botet, Juan

AU - Chillarón, Juan J.

AU - Benaiges, David

AU - Flores Le-Roux, Juana A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - © 2015 Sociedad Española de Cardiología. The American College of Cardiology and the American Heart Association have produced new guidelines on cholesterol levels and the risk of atherosclerotic cardiovascular disease that represent a paradigm shift in the treatment of hypercholesterolemia because they abandon the use of the low-density lipoprotein cholesterol level as the therapeutic target and focus instead on the clinical benefits of statins. This article presents the key features of these guidelines and highlights both their strengths and areas open to improvement.

AB - © 2015 Sociedad Española de Cardiología. The American College of Cardiology and the American Heart Association have produced new guidelines on cholesterol levels and the risk of atherosclerotic cardiovascular disease that represent a paradigm shift in the treatment of hypercholesterolemia because they abandon the use of the low-density lipoprotein cholesterol level as the therapeutic target and focus instead on the clinical benefits of statins. This article presents the key features of these guidelines and highlights both their strengths and areas open to improvement.

KW - Cardiovascular disease

KW - Cardiovascular risk

KW - Cholesterol

KW - Clinical guidelines

KW - Statins

U2 - 10.1016/S1131-3587(15)70120-2

DO - 10.1016/S1131-3587(15)70120-2

M3 - Article

SN - 1131-3587

VL - 15

SP - 18

EP - 21

JO - Revista Espanola de Cardiologia Suplementos

JF - Revista Espanola de Cardiologia Suplementos

IS - S1

ER -

United States Guidelines on Dyslipidemia. Strengths and Weaknesses

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this